[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Oscar Lambret\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":387},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,50,76,104,128,157,183,211,252,279,305,339,367],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100631983","phase-2-assessment-of-the-long-term-efficacy-of-moderately-hypofractionated-neoadjuvant-radiotherapy-soft-tissue-sarcoma-in-the-limbs-or-trunk-wall-100631983",false,"NCT07507773","Assessment of the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall","Phase II Clinical Trial Assessing the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall, Incorporating Translationnal Research","NEORASARC","Inclusion Criteria:\n\n* Patient aged ≥ 18 years ;\n* Localised sarcoma of a limb, the root of a limb, or the trunk wall ;\n* Histologically confirmed diagnosis of soft tissue sarcoma regardless of the grade ;\n* Diagnosis biopsy performed at Centre Oscar Lambret, with specimen available for translational research ;\n* Indication of neoadjuvant radiotherapy according to the multidisciplinary consultation meeting ;\n* Tumor considered operable with a curative intent and conservative intent according to the multidisciplinary consultation meeting ;\n* Affiliation to the French National Social Security System ;\n* Informed and signed consent\n\nExclusion Criteria:\n\n* Metastatic disease (including local lymph node diffusion) ;\n* Visceral or retroperitoneal sarcoma ;\n* Tumor considered inoperable even after radiotherapy, according to the multidisciplinary consultation meeting ;\n* Indication of neoadjuvant or adjuvant chemotherapy ;\n* Ewing tumor of soft tissue, desmoid tumor, embryonal or alveolar rhabdomyosarcoma ;\n* Pregnant or breastfeeding women ;\n* Patients under protective measures ;\n* Patient refusal.","ALL","18 Years",{"count":20,"type":21},135,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This trial aims to assess the long-term efficacy of moderately hypofractionated neoadjuvant radiotherapy for soft tissue sarcoma in the limbs or trunk wall. The primary outcome is local disease control, assessed by the cumulative incidence of progression\u002Frecurrence.\n\nAfter informed consent has been obtained and eligibility criteria have been checked, a baseline assessment will be performed followed by the experimental treatment: intensity-modulated radiotherapy with a moderately hypofractionated regimen consisting in 15 fractions of 2.7 Gy administered over 3 weeks.\n\na follow-up assessment will be performed 3 to 4 weeks after the last radiotherapy session.\n\nTumor resection will be performed 4 to 8 weeks after the radiotherapy. Patients will then be followed up until the end of the study; planned 5 years after the last inclusion.\n\nRadiotherapy will be evaluated in terms of safety and efficacy.",[27,28,29,30],"Soft Tissue Sarcoma Adult","Soft Tissue Sarcoma (Excluding GIST)","Soft Tissue Sarcoma of the Trunk and Extremities","Soft Tissue Sarcoma of the Limb",[32,33,34,35,36],"Sarcoma","Trunk","Limb","Radiotherapy","Neoadjuvant","RECRUITING","2026-06-18",{"date":40,"type":41},"2026-06-22","ACTUAL",{"date":43,"type":21},"2026-06-01",{"date":45,"type":21},"2035-06-01",{"name":47,"class":48},"Centre Oscar Lambret","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":49},"100590624","prospective-clinico-biological-database-of-patients-with-ovarian-andor-peritoneal-andor-fallopian-tube-carcinoma-100590624","NCT06969833","Prospective Clinico-biological Database of Patients With Ovarian and\u002For Peritoneal and\u002For Fallopian Tube Carcinoma","Study of Prognostic Factors Associated With Overall Survival in Patients Initially Treated for Advanced Ovarian and\u002For Peritoneum and\u002For Fallopian Tubes Carcinoma: Analysis Using a Prospective Clinico-Biological Database","BCB-OVAIRE","Eligibility criteria for pre-registration:\n\n* Patient aged 18 or over\n* Informed consent warranted\n* Patient affiliated to a social security regimen\n* Suspected diagnosis of advanced and invasive ovarian cancer and\u002For primary peritoneal cancer and\u002For fallopian tube cancer (IIB to IV FIGO stages)\n* Pre-registration during standard care at the Oscar Lambret Centre, from diagnosis and before confirmation of definitive FIGO stage\n\nNon eligibility criteria for pre-registration:\n\n* Patient deprived of liberty or under curatorship or guardianship\n* Refusal to participate\n\nInclusion criteria:\n\n• Confirmed diagnosis of advanced and invasive ovarian cancer and\u002For primary peritoneal cancer and\u002For fallopian tube cancer (IIB to IV FIGO stages)\n\nExclusion criteria:\n\n• Dismissed diagnosis of advanced and invasive ovarian cancer and\u002For primary peritoneal cancer and\u002For fallopian tube cancer , or other type of cancer","FEMALE",{"count":60,"type":21},371,[62],"NA","Cancer of the ovary and\u002For peritoneum and\u002For fallopian tube have a very poor prognosis, and require the implementation of collaborative research tools and new innovative therapies. The main objective of this study is to implement prognostic model of overall survival on patients included prospectively as part of the initial treatment of advanced ovarian and\u002For peritoneum, and\u002For fallopian tubes carcinoma (this cohort corresponds to the \"Turquoise\" care pathway of the Oscar Lambret Center) regardless of the treatment carried out,, integrating both patient's and tumor's characteristics. A clinical and biological database is implemented for this purpose.\n\n371 patients will be recruited over a 5-year period at the Oscar Lambret Center.\n\nThe active participation of each patient will be 2 years (from the date of pre-registration until the end of study participation, defined by the date of the last intervention specific to the research), then the data from standard care and survival data will be collected until the last follow-up of the last patient, 2 years after the last pre-registration.",[65,66,67],"Cancer of the Ovary","Cancer of the Fallopian Tube","Peritoneal Cancer","2026-03-25",{"date":70,"type":41},"2026-03-30",{"date":72,"type":41},"2025-06-27",{"date":74,"type":21},"2032-06-27",{"name":47,"class":48},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":58,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":49},"100578120","phase-2-serratus-plane-block-spb-versus-capsacine-versus-botox-a-for-chronic-neuropathic-pain-in-post-mastectomy-syndrome-100578120","NCT06807164","Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome","SerCaBot","Inclusion Criteria :\n\n1. Women aged ≥ 18 years;\n2. Unilateral breast cancer treated by total or partial mastectomy:\n\n   * with sentinel lymph node technique (SLN) or axillary dissection;\n   * with or without immediate reconstruction using a prosthesis;\n   * associated or not with radiotherapy and\u002For chemotherapy;\n3. Presenting moderate to severe chronic neuropathic pain, defined by:\n\n   * Numerical Pain Scale (NPS) ≥ 3 and DN4 ≥ 4,\n   * on a localised aera ((≤ 240 cm²), at the surgical site, in the axillary hollow, or on the inner side of the ipsilateral arm,\n   * between 3 and 9 months after breast surgery,\n   * with indication of additional locoregional treatment in complement to a systemic treatment of chronic neuropathic pain, as recommended by the SFETD - French Society for the Study and Treatment of Pain (tricyclic antidepressants or IRSNA or gabapentinoid PLUS lidocaine patch, at the appropriate dosage) and implemented for at least 4 weeks;\n4. Patient affiliated with a health insurance plan;\n5. Patient informed and having consented to participate in the trial.\n\nExclusion Criteria :\n\n1. Ipsilateral breast cancer recurrence, regardless of the first treatment;\n2. History of breast or thoracic surgery prior to mastectomy with residual pain;\n3. Painful polyneuropathy related to chemotherapy requiring treatment;\n4. Ongoing or planned loco-regional adjuvant radiotherapy within the next 8 weeks;\n5. Treatment area not suitable for potential botulinum toxin type A treatment;\n6. Breast reconstruction using flap or lipomodelling;\n7. Indication for breast reconstruction within the next 8 weeks;\n8. Chronic pain of another etiology such as:\n\n   * Neuropathic pain secondary to a neuroma (localized pain),\n   * Radiodermatitis,\n   * Phantom breast pain,\n   * Lymphedema,\n   * Complex regional pain syndrome,\n   * Adhesive capsulitis,\n   * Fibromyalgia;\n9. Hypersensitivity or allergy to anesthetics, capsaicin, naropein, clonidine hydrochloride, an amide-type local anesthetic, botulinum toxin type A, or any excipient contained in the preparations;\n10. Infection or inflammation at the injection site;\n11. Therapeutic\u002Feffective anticoagulation;\n12. Clinical signs or medical history leading to the diagnosis of:\n\n    * Hemostasis disorder,\n    * Local infection,\n    * Severe renal insufficiency (creatinine clearance \\\u003C 30 mL\u002Fmin),\n    * Thrombocytopenia \\\u003C 50,000 platelets\u002Fmm3;\n13. Generalized muscle activity disorders (e.g., myasthenia, Lambert-Eaton syndrome);\n14. Heart rate lower than 60\u002Fminute;\n15. Severe bradyarrhythmia due to sick sinus syndrome or second or third-degree atrioventricular block;\n16. State of depression (HADS score ≥ 11);\n17. Other contraindication to any of the study treatments;\n18. Inability for the patient to follow the study schedule;\n19. Inability for the patient or the healthcare team to perform the treatment within 2 weeks;\n20. Pregnant or breastfeeding women, women who are able to conceive and who do not use a highly effective method of contraception during the trial and for at least 1 month after the end of treatment ;\n21. Patient under guardianship or curatorship.",{"count":84,"type":21},123,[24],"The goal of this phase II clinical trial is to study the effectiveness of a treatment with Serratus Plane Block (SPB) or Botox-A in comparison with capsaicin for the control of chronic neuropathic pain of post-mastectomy syndrom, that is not adequately managed by systemic treatment alone. The primary outcome will be the pain evaluation at 8 weeks.\n\n123 patients with chronic neuropathic pain of post-mastectomy syndrom insufficiently relieved by systemic treatment alone will be recruited over 24 months at the Centre Oscar Lambret.\n\nPatients will be randomly assigned to one of three treatment groups (41 patients per group):\n\nCapsaicin Botulinum toxin A SPB\n\nPatients will be followed for 24 weeks after the study treatment. The follow-up will include remote evaluation and 2 medical visits during which pain and quality of life will be assessed.",[88],"Post-Mastectomy Neuropathic Pain Syndrome",[90,91,92,93,94,95,96],"Breast cancer","Chronic neuropathic pain","Post-mastectomy pain","Serratus Plane Block (SPB)","Capsaicin","Pain management","Botulinum toxin type A",{"date":98,"type":41},"2026-03-27",{"date":100,"type":21},"2026-03-31",{"date":102,"type":21},"2027-12-30",{"name":47,"class":48},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":122,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":49},"100456439","prospective-cohort-with-clinic-biologic-database-of-patients-treated-by-immunotherapy-100456439","NCT05223608","Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy","ImmuCCo","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Beginning a first immunotherapy by immune checkpoint inhibitor - anti-PD1 (Programmed cell Death protein-1), anti-PDL1 (Programmed cell Death protein-1 ligand), anti-CTLA4 (Cytotoxic T-Lymphocyte associated protein 4), as monotherapy or in combination, in the Centre Oscar Lambret (COL)\n* In neo-adjuvant, adjuvant, recurrence or metastatic situation\n* Suffering from solid tumor histologically documented\n* Signed written informed consent\n* Patient covered by the French \" \"Social Security\" regime If the patient is already enrolled in clinical trial involving immunotherapy, the agreement of the sponsor of this new trial will be sought before his\u002Fher inclusion.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Patient already treated by immunotherapy by immune checkpoint inhibitor\n* Person under guardianship\n* Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons)",{"count":112,"type":21},651,[62],"ImmuCCo-1905 is a monocentric interventional study on patients treated by immunotherapy, which consist in establishment of a prospective clinic-biologic database over 5 years, associated with a biobank. This database will allow carrying out works aiming at assessing immunotherapy in real life situation.",[116],"Solid Tumor, Adult",[118,119,120,121],"Prospective cohort","Clinic-biologic database","Solid tumor","Immunotherapy",{"date":70,"type":41},{"date":124,"type":41},"2022-03-03",{"date":126,"type":21},"2028-03",{"name":47,"class":48},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":146,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":49},"100630625","benefits-of-early-collaboration-between-oncologists-and-palliative-care-physicians-in-cases-of-unplanned-hospitalization-for-patients-with-metastatic-cancer-100630625","NCT07490106","Benefits of Early Collaboration Between Oncologists and Palliative Care Physicians in Cases of Unplanned Hospitalization for Patients With Metastatic Cancer","SPPC","Inclusion Criteria:\n\n* Subjects aged 18 years and older;\n* Diagnosed with metastatic or locally advanced digestive, gynecological, ENT, or sarcoma cancer;\n* Currently undergoing systemic palliative treatment (no prospect of cure);\n* Hospitalized on an unscheduled basis (i.e., unplanned hospitalization for scheduled oncology treatments);\n* Patient covered by the French social security system;\n* Informed consent, written and signed.\n\nExclusion Criteria:\n\n* PS (WHO) = 4;\n* Patient receiving end-of-life care;\n* Patient opposed to the use of medical data for research purposes;\n* Person deprived of liberty or under guardianship;\n* Inability to undergo medical monitoring for the trial for geographical, social, or psychological reasons.",{"count":136,"type":21},493,[62],"This is a multicenter, national, interventional, cluster-randomized study, \"stepped wedge\" design. This study includes patients with metastatic or locally advanced digestive, gynecological, ENT, or sarcoma cancer, currently undergoing systemic palliative treatment and hospitalized on an unscheduled basis. The study will aim to evaluate the impact of early palliative care implementation for patients with metastatic or advanced cancer identified during an unplanned hospitalization.",[140,141,142,143,144,145],"Cancer","Sarcoma Metastatic","Gynaecologic Cancer","Digestive Cancers","ENT Cancer","Metastatic Cancer or Locally Advanced",[147],"Metastatic or Locally Advanced digestive, gynecological, ENT, or sarcoma cancer","NOT_YET_RECRUITING","2026-03-19",{"date":151,"type":41},"2026-03-24",{"date":153,"type":21},"2026-04",{"date":155,"type":21},"2031-04",{"name":47,"class":48},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":164,"maxAge":18,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":168,"conditions":169,"keywords":174,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":49},"100608511","proof-of-concept-study-of-the-snoezelen-device-on-anxiety-symptoms-in-patients-hospitalized-for-chemotherapy-in-a-pediatric-oncology-department-100608511","NCT07202507","Proof-of-Concept Study of the SNOEZELEN Device on Anxiety Symptoms in Patients Hospitalized for Chemotherapy in a Pediatric Oncology Department","SNOOZE","Inclusion Criteria:\n\n* New patient\n* Treated in the Paediatrics\u002FAJA department of the Oscar Lambret Centre for cancer (all types of cancer)\n* Hospitalisation for several days\n* Highly emetogenic chemotherapy treatment: this corresponds to all in-patient treatments carried out in the Paediatrics\u002FAJA department.\n* Age at diagnosis : ≥ 8 years and \\\u003C 18 years.\n* French language\n* Information for the patient and those with parental authority; consent signed by the patient and those with parental authority.\n* Valid social security cover\n\nExclusion Criteria:\n\n* Contraindication to SNOEZELEN:\n\n  * Claustrophobia\n  * Presence of psychiatric, addictive or cognitive disorders that would prevent compliance with the protocol requirements;\n* State of health not allowing participation in the study (severe fatigue, symptoms refractory to treatment).\n* Pregnant or breast-feeding women","8 Years",{"count":166,"type":21},20,[62],"The goal of this clinical trial is to evaluate whether the Snoezelen multisensory relaxation approach can reduce anxiety symptoms in children and adolescents aged 8 to 17 years hospitalized for chemotherapy in a pediatric oncology unit.\n\nResearchers will compare patients' symptoms during a chemotherapy cycle with Snoezelen sessions to a previous cycle without Snoezelen, in order to assess changes in psychological and physical well-being.\n\nParticipants will:\n\n* Be enrolled between their first (without Snoezelen) and second (with Snoezelen) chemotherapy cycles\n* Complete self-report questionnaires on anxiety, depression, quality of life, and nausea\n* Receive 45-minute Snoezelen sessions every two days during their second hospitalization\n* Participate in a semi-structured interview after the final session\n* Provide data on medications (anxiolytics, antiemetics) and vomiting frequency during both hospitalizations",[170,171,172,173],"Snoezelen","Pediatric Cancer","Symptomatologie Anxieuse","Chimiothérapie",[170,171],"2026-03-16",{"date":177,"type":41},"2026-03-18",{"date":179,"type":21},"2027-09",{"date":181,"type":21},"2027-10-31",{"name":47,"class":48},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":58,"minAge":191,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":200,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":49},"100585285","efficacy-and-safety-of-vaginal-radiofrequency-for-vulvovaginal-atrophy-in-breast-cancer-patients-100585285","NCT06900374","Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients","RF-Vaginale : Randomised Phase III Trial Evaluating the Efficacy and Safety of Vaginal Radiofrequency in the Management of Vulvovaginal Atrophy and Dryness in Patients Treated for Breast Cancer","RF-Vaginale","INCLUSION CRITERIA :\n\n* Patient over 40 years\n* Presenting disabling vaginal dryness symptoms despite well-administered local moisturizing treatment, attested by a vaginal dryness score ≥3\n* Patient undergoing adjuvant treatment for breast cancer\n* Patient treated with aromatase inhibitors +\u002F- LHRH agonist for at least 3 months with a planned remaining duration of at least 12 months\n* Patient affiliated to a social security organization\n* Patient having signed the informed consent for the present study\n\nEXCLUSION CRITERIA:\n\n* Contraindications related to the radiofrequency technique:\n\n  * Ongoing urinary tract infection\n  * Pacemaker\n  * IUD intrauterine device\n  * Pregnancy\n* Mucocutaneous disease with vulvovaginal localization: infection, sore, scleratrophic lichen, psoriasis, eczema, etc.\n* Neurodegenerative disease with perineal involvement\n* Current or recent treatment (within the last 12 months) with other physical methods: vaginal laser, photobiomodulation, PRP injection, hyaluronic acid injection or lipo-modeling.\n* Pregnant or breast-feeding women\n* Patients under guardianship or trusteeship.","40 Years",{"count":193,"type":21},75,[62],"This Phase III, randomized, balanced, parallel-group, multicenter trial aims to evaluate the effect of vaginal radiofrequency on symptoms of vaginal dryness at six months. The study compares vaginal radiofrequency treatment with non-hormonal hydration therapy in a population of patients undergoing adjuvant hormonal therapy with aromatase inhibitors, with or without LHRH agonists, for breast cancer.\n\nPatients will be randomly assigned to one of two parallel treatment groups until the six-month assessment:\n\nThe first group will receive the reference treatment, which consists of local hydration using a hyaluronic acid-based treatment applied three times a week. Additionally, investigators may incorporate supportive measures at their discretion, such as physiotherapy or vaginal dilators.\n\nThe second group will receive the same reference treatment combined with vaginal radiofrequency therapy. This intervention consists of three sessions, each spaced 4 to 6 weeks apart.",[197,198,199],"Vaginal Dryness","Breast Cancer","Vulvovaginal Atrophy",[201,202,203,204],"Vaginal dryness","vaginal atrophy","vaginal radiofrequency","breast cancer",{"date":177,"type":41},{"date":207,"type":41},"2025-06-12",{"date":209,"type":21},"2028-06",{"name":47,"class":48},{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":58,"minAge":219,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":231,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":251},"100571905","risk-reducing-strategies-including-fimbriectomy-in-women-with-a-germline-mutation-predisposing-to-ovarian-or-pelvic-cancer-100571905","NCT06726330","Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer","Evaluation of Risk Control of Advanced Stage Tubo-ovarian or Primary Peritoneal Carcinoma Associated With Ovarian Carcinoma Risk-reducing Strategies, Including Fimbriectomy With Delayed Oophorectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer","FIMBRIMENOP","Inclusion Criteria:\n\n1. Woman between 35 to 50 years\n2. Addressed to or followed in an oncogenetic counselling\n3. Identified risk of tubo-ovarian or primary peritoneal carcinoma based on mutational status (BRCA1, BRCA 2, RAD51C, RAD51D, PALB2). The list of considered mutations may be extended during the study.\n4. Written informed consent\n5. Patient covered by the French \"Social Security\"\n\nExclusion Criteria:\n\n1. Prior bilateral oophorectomy and\u002For bilateral salpingectomy for any reason (prophylactic surgery or other)\n2. Personal history of ovarian, fallopian tube or primary peritoneal cancer\n3. Menopause defined by\n\n   • In women without prior chemotherapy If no prior hysterectomy: the absence of menses for at least 12 months, or FSH \\> 20 UI\u002FL with low estrogen level with no identified gynecological or endocrine explanation. Amenorrhea related to an intrauterine device, vaginal ring or estrogen-progestin pill will not be considered as menopause.\n\n   If prior hysterectomy: FSH \\>20 UI\u002FL with low estrogen level (with or without vasomotor symptoms, genitourinary symptoms)\n   * In women with prior chemotherapy: the absence of menses for at least 24 months\n   * In all women with progesterone-loaded intra-uterine device (IUD): FSH \\> 20 UI\u002FL with low estrogen level\n4. Inability to comply with medical follow-up of the trial (geographical, social or psychological reasons)\n5. Patient under guardianship or curatorship","35 Years","50 Years",{"count":222,"type":21},1100,[62],"• FIMBRIMENOP-2402 study aims to evaluate the long-term management of cancer risks in premenopausal women who have a genetic predisposition to tubo-ovarian or primary peritoneal carcinoma, such as mutations in BRCA1, BRCA2, RAD51C, RAD51D, or PALB2 genes. This study offers an alternative to standard preventive surgery (bilateral salpingo-oophorectomy or BSO) by exploring the use of fimbriectomy (removal of the fallopian tube's fimbria) followed by delayed oophorectomy (removal of ovaries at menopause).\n\nIt's a pragmatic multicenter trial conducted across various medical centers, employing a non-randomized controlled preference design to compare two preventive surgical strategies:\n\n1. Fimbriectomy followed by delayed oophorectomy (F-DO).\n2. Bilateral salpingo-oophorectomy (BSO).\n\nThe primary objective is to compare the long-term efficacy of two preventive surgical strategies :\n\n1. Fimbriectomy followed by delayed oophorectomy (F-DO).\n2. Bilateral salpingo-oophorectomy (BSO).\n\nAs for the design of the study, participants choose their preferred surgical strategy during or after oncogenetic counseling, ensuring patient autonomy in decision-making.\n\n• Follow-Up: Long-term follow-up includes clinical assessments, data collection from medical networks, and integration with national health databases to track outcomes up to the age of 70.\n\nThis is the first French comparative study in real-world settings and is classified as interventional research (RIPH1) under French regulations, given the need to validate fimbriectomy efficacy.",[226,227,228,229,230],"Tubo-ovarian Carcinoma","High-grade Serous Carcinoma","Primary Peritoneal Carcinoma Stage III","Primary Peritoneal Carcinoma Stage IV","Primary Peritoneal Carcinoma",[232,233,234,235,236,237,238,239,240,241,242,243],"Tubo-ovarian carcinoma","Primary peritoneal carcinoma","BRCA1\u002F2 mutations","RAD51C\u002FD mutations","PALB2 mutation","Preventive surgery","Fimbriectomy","Bilateral salpingo-oophorectomy","BSO","Cancer prevention","Premenopausal women","Genetic predisposition to cancer",{"date":245,"type":41},"2026-03-17",{"date":247,"type":21},"2027-03",{"date":249,"type":21},"2071-03",{"name":47,"class":48},23,{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":58,"minAge":260,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":49},"100566686","phase-2-clinical-trial-evaluating-secondary-hpv-vaccination-after-treatment-of-high-grade-cervical-lesions-100566686","NCT06658405","Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions","Phase 2 Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions (HPV2-2303)","HPV2","Inclusion Criteria:\n\n1. Common eligibility criteria for the study (for both cohorts) :\n\n   1. Female patient over 45 years old\n   2. Patient treated by conization for high-grade cervical epithelial lesion\n   3. Positive HPV test at the 6-month post-operative control (a delay of 6 to 12 months will be accepted), leading to an indication for a control colposcopy (+\u002F- biopsy) according to standard surveillance practices.\n   4. N.B. : Patients with abnormalities at the initial control colposcopy and\u002For positive biopsy remain eligible for the study, whether vaccinated or not.\n2. Additional eligibility criteria for the clinical trial (Vaccinated patients cohort)\n\n   1. No contraindication to HPV vaccination with Gardasil 9\n   2. Patient consented to HPV vaccination with Gardasil 9\n   3. Affiliated with a social security system\n   4. Informed and signed written consent provided\n   5. N.B. : Patients infected with HIV are eligible for the vaccine trial provided they are on antiretroviral therapy.\n3. Inclusion criteria for the data study (Non-vaccinated patients cohort)\n\n   1. Patient eligible for the study (a) and not eligible for the clinical trial (b) due to:\n\n      * refusal of vaccination, or\n      * A contraindication to vaccination\n   2. No objection to the use of their personal data for research purposes\n\nN.B. : A patient who initially refused vaccination may later request to be vaccinated as part of the trial after signing the consent form. The vaccine trial analysis will include all patients who started vaccination within 6 months after the initial HPV control test.\n\nExclusion Criteria:\n\n1. Common exclusion criteria for the study (for both cohorts)\n\n   1. History of primary HPV vaccination\n   2. History of HPV-induced invasive cancer (cervical, vaginal, vulvar, anal, oropharyngeal cancer)\n2. Exclusion criteria for the clinical trial (Vaccinated patients cohort)\n\n   1. Patient refusing HPV vaccination\n   2. Patient with a contraindication to HPV vaccination with Gardasil 9\n   3. Patient deprived of liberty or under guardianship\n3. Exclusion criteria for the data study (Non-vaccinated patients cohort) a) Opposition to the use of their personal data for research purposes","45 Years",{"count":262,"type":21},85,[24],"This is a single-center, Phase II interventional study evaluating secondary HPV vaccination after treatment of high-grade cervical lesions. The study aims to estimate the rate of HPV clearance within two years following an initial positive HPV control test in women over 45 years of age who are chronic HPV carriers and have undergone treatment for high-grade intraepithelial cervical lesions, and who receive HPV vaccination.\n\nThe study includes two cohorts:\n\n1. Eligible patients who consent to vaccination will participate in a prospective, single-center, single-arm, interventional clinical trial (Category 2).\n2. Non-vaccinated patients will be included in a non-interventional observational study, with no changes to their standard care.",[266],"Cervical Lesion",[268,269,270,271,272],"HPV","oncology","secondary prevention","cervix","vaccination",{"date":177,"type":41},{"date":275,"type":41},"2025-01-13",{"date":277,"type":21},"2031-12-31",{"name":47,"class":48},{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":22,"phases":289,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":298,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":304},"100532319","superiority-trial-evaluating-digitalized-information-media-for-patients-with-advanced-sarcomas-receiving-systemic-treatment-100532319","NCT06211257","Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.","Phase 3 Superiority Trial Evaluating the Benefit of Dematerialized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment for Metastatic or Locally Advanced Disease.","ePPS","Inclusion Criteria:\n\n* Sarcomas of soft tissues or viscera ;\n* Inoperable metastatic or locally advanced disease ;\n* Indication for systemic treatment with pazopanib, trabectedine, eribulin, ifosfamide or dacarbazine monotherapy ;\n* Patient covered by French social security ;\n* Written, signed, informed consent ;\n\nExclusion Criteria:\n\n* Prior inclusion in ePPS trial for a prior systemic treatment ;\n* Poor understanding of French ;\n* Difficulty accessing a computer ;\n* Pregnant or nursing woman ;\n* Person deprived of liberty or under guardianship ;\n* Impossibility of undergoing medical follow-up for geographical, social or psychological reasons.",{"count":288,"type":21},377,[62],"ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information\u002FPCP for patients with advanced sarcomas receiving systemic treatment.\n\nParticipants will be randomised to an experimental group or a control group. Patients in the experimental group will receive the dematerialised PCP in addition to the standard PCP while patients in the control group will receive the standard PCP alone.\n\nAll patients will be followed until the end of second-line treatment, the start of a new line of treatment, or until the 24-month follow-up.",[141,292],"Locally Advanced Soft Tissue Sarcoma",[32,294,295,296,297],"Advanced","Dematerialised","Care","Plan",{"date":177,"type":41},{"date":300,"type":41},"2024-05-29",{"date":302,"type":21},"2030-04",{"name":47,"class":48},11,{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":22,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":338},"100477701","phase-2-assessment-of-compliance-with-monitoring-conducted-by-a-physician-in-person-or-by-a-nurse-in-remote-monitoring-100477701","NCT05500391","Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring","Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring","SUR-CAN","Inclusion Criteria:\n\n* Positive diagnosis (anatomopathology) of tumor within 12 months\n* Patient 18 years of age or older\n* Patient with one of the following conditions:\n\n  1. Desmoid fibromatosis of the abdominal wall operated on or under active surveillance\n  2. Stage I testicular seminoma (whether or not treated with carboplatin AUC7)\n  3. Stage I non-seminomatous germ cell tumor (with or without adjuvant BEP chemotherapy)\n  4. Operated GIST with low risk of relapse\n  5. Rare gynecological tumors (sex cord and stromal tumors; germ cell tumors of the ovary, clear cell adenocarcinoma, mucinous adenocarcinoma of the ovary, borderline tumors, small cell carcinoma, ovarian and uterine carcinosarcoma, low grade serous tumors), operated\n  6. Low-grade glioma, operated\n  7. Low-grade neuroendocrine tumor, treated by surgery alone\n* Patient who has given consent to participate in the study\n\nExclusion Criteria:\n\n* Contraindication to imaging tests required for the surveillance plan\n* No telephone\n* Patient under guardianship or curatorship",{"count":314,"type":21},88,[24],"This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (\\\u003C12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan, established for each patient according to national guidelines, when the surveillance is conducted in person by a hospital-based physician (control arm) or remotely by a trained nurse (experimental arm).",[318,319,320,321,322,323,324,325,326,327,328,329,330,331],"Stage I Testicular Seminoma","Stage I Testicular Nonseminomatous Germ Cell Tumor","Gastrointestinal Stromal Tumors","Ovarian Germ Cell Tumor","Adenocarcinoma, Clear Cell","Borderline Ovarian Tumor","Sex Cord-Stromal Tumor","Mucinous Adenocarcinoma of Ovary","Carcinoma, Small Cell","Carcinosarcoma, Ovarian","Serous Tumor of Ovary","Glioma","Neuroendocrine Tumors","Aggressive Fibromatosis of Abdominal Wall (Disorder)",{"date":177,"type":41},{"date":334,"type":41},"2024-02-28",{"date":336,"type":21},"2032-07",{"name":47,"class":48},3,{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":17,"minAge":347,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":22,"phases":351,"briefSummary":353,"conditions":354,"keywords":356,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":366},"100468825","phase-1-metronomic-chemotherapy-in-wilms-tumor-metrowilms-1906-100468825","NCT05384821","Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)","Phase 1-2 Trial Evaluating Metronomic Chemotherapy in Patients With a Relapsed or Refractory Wilms Tumor","MetroWilms","Inclusion Criteria:\n\n* Patient ≥18 months old and ≤ 17 years old\n* Relapsed or refractory Wilms tumor, histologically proven at diagnosis\n* After at least 2 lines of chemotherapy (conventional or high dose, which may include the trial molecules) or after 1 line for high risk relapse for which there would not be any curative therapy. If 1 line for high risk relapse, the enrolment should be confirmed by coordinators.\n* Radiologically measurable or evaluable disease (visible, target or non-target-lesion on MRI or CT-scan)\n* Performance status: Karnofsky performance status (for patients \\>16 years of age) or Lansky Play score (for patients ≤16 years of age) ≥ 70%.\n* Able to take oral medication or nasal gastric tube or authorized gastrostomy\n* Adequate biological criteria:\n\n  * Neutrophils \\> 1000\u002Fmm3 ; Platelets \\> 75 000\u002Fmm3\n  * Transaminases (ALT\u002F AST) ≤ 3 times ULN (or ≤ 6 times ULN if liver metastasis); total bilirubin ≤ 2 ULN (except in case of Gilbert's disease)\n* Creatinine ≤ 1,5 ULN or clearance ≥ 60 mL\u002F min\u002F 1,73m2 (In case of doubt, to be confirm by assessment of cystatin )\n* Females of childbearing potential must have a negative seric pregnancy test within 7 days prior to initiation of treatment.\n* Sexually active patients must agree to use adequate and appropriate contraception (at least one highly effective contraception or two complementary methods of contraception), 1 month before beginning of treatment while on trial drug and for 7 months after stopping the trial drug for female patients and after 6 months for male patients.\n* Written informed consent from parents\u002Flegal representative, patient, and age-appropriate assent before any trial-specific screening procedures according to national guidelines.\n* Patient covered by the French \"Social Security\" regime\n\nExclusion Criteria:\n\n* Prior history of other cancer within 5 years\n* Chemotherapy or radiotherapy of target lesion within 3 weeks prior to inclusion\n* Target therapy within less than 5 \\* half-life of the substance prior to inclusion\n* Major surgery within 15 days prior to inclusion\n* Presence of any NCI-CTCAE v5 grade ≥ 2 cardiac, hepatic, pulmonary or renal toxicity\n* Severe myelosuppression\n* Severe peripheral neuropathy (grade ≥ 2)\n* Fructose intolerance\n* Inflammatory bowel chronic disease and\u002For intestinal obstruction\n* Patients with demyelinating form of Charcot-Marie-Tooth disease\n* Known active viral hepatitis or known human immunodeficiency virus (HIV) infection or any other uncontrolled infection.\n* Known hypersensitivity to dacarbazine (DTIC), isotretinoin or to any of the trial drugs, trial drug classes, excipients in the formulation\n* Hyperlipidemia and hypervitaminosis A\n* Vaccination with a live attenuated vaccine within 1 month prior to inclusion\n* Pregnant or breastfeeding patients\n* Inability to comply with medical follow-up of the trial (geographical, social or psychological reasons)","18 Months","17 Years",{"count":350,"type":21},28,[352,24],"PHASE1","This is a multicenter, interventional, non-randomized study among patients with a relapsed or refractory Wilms tumor. The study will aim to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy.",[355],"Wilms Tumor",[357,358,355,359],"Multidrug chemotherapy","metronomic chemotherapy","Renal cancer",{"date":177,"type":41},{"date":362,"type":41},"2022-09-14",{"date":364,"type":21},"2028-10",{"name":47,"class":48},18,{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":378,"phases":4,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":49},"100439829","study-to-determine-the-antitumor-activity-of-new-car-macrophages-in-breast-cancer-patients-derived-organoids-100439829","NCT05007379","Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids","Cohort Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids (CARMA)","CARMA","Inclusion Criteria:\n\n* Male or female aged 18 years or more\n* Histologically confirmed breast cancer at any stage\n* Requiring surgery or tumor biopsy as standard of care\n* Any or no systemic treatment\n* Signed informaed consent\n* Health insurance coverage\n\nExclusion Criteria:\n\n* Opposed to biospecimen collection","100 Years",{"count":377,"type":21},100,"OBSERVATIONAL","Cell-based immune therapy using modified macrophages is a promising therapeutic approach in breast cancer. The objective of this cohort study is to collect tumor samples to develop patients' derived organoids to test the antitumor activity of newly developed CAR-macrophages. Other biological samples will be collected such as blood to analyze the host inflammatory status.",[198],{"date":177,"type":41},{"date":383,"type":41},"2021-11-02",{"date":385,"type":21},"2027-12-01",{"name":47,"class":48},""]